Erasca class action lawsuit
Analysis based on 6 articles · First reported Jul 07, 2026 · Last updated Jul 16, 2026
Erasca's stock price fell nearly 59% combined on April 27, 2026 due to the patent infringement allegations and adverse clinical data. The class action lawsuit may result in significant financial liability for Erasca and further erode investor confidence.
A securities class action lawsuit has been filed against Erasca (Nasdaq: ERAS) in the United States — United States District Court for the Southern District of California, alleging violations of the Securities Exchange Act of 1934. The lawsuit claims that Erasca and certain executives made false or misleading statements regarding its drug candidate ERAS-0015, including improper comparisons to Revolution Medicines and failure to disclose patent infringement risks. On April 27, 2026, Erasca disclosed receiving a patent infringement letter from Revolution Medicines, causing an 11% stock drop. Later that day, Erasca reported Phase I clinical data revealing a patient death, leading to a further 48% decline. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 have until August 10, 2026 to seek lead plaintiff appointment. The law firm Robbins Geller Rudman & Dowd LLP LLP is representing the class.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard